Author details

Full Name

Giancarlo Comi

Affiliation

ORCID

Career Start Year

1975

Papers

1204

H Index

120

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38084497	A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.	Mult Scler	2024
36723685	Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon Î²-1a.		2023
37745914	Safety and efficacy with alemtuzumab over 13â¿¿years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.		2023
37702323	Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury.	Clin Chem Lab Med	2023
37610702	Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).		2023
37089424	Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis.	Front Physiol	2023
37405689	Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.		2023
37086648	The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.		2023
36776745	Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study.	Mult Scler J Exp Transl Clin	2023
36824421	Editorial: Fatigue in multiple sclerosis-A current perspective.		2023
37323584	Visual evoked potentials waveform analysis to measure intracortical damage in a preclinical model of multiple sclerosis.	Front Cell Neurosci	2023
37447866	Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis.	Sensors (Basel)	2023
37383099	A novel mutation in an Italian patient with non-fluent variant of primary progressive aphasia at onset: a longitudinal case report.		2023
37382446	Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis.		2023
37314699	A safety review of current monoclonal antibodies used to treat multiple sclerosis.		2023
37188941	Age-induced alterations of granulopoiesis generate atypical neutrophils that aggravate stroke pathology.		2023
37002504	Preserving the brain: forum on neurodegenerative diseases.	Neurol Sci	2023
36624312	Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study.	Nat Med	2023
37236124	HNF4Î±, SP1 and c-myc are master regulators of CNS autoimmunity.		2023
37232279	Sars-CoV2 infection in pregnant women with multiple sclerosis.		2023
36675783	Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach.	J Pers Med	2023
34748672	Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.	European Journal of Neurology	2022
35530174	Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach-perspectives from the International Progressive MS Alliance.	Multiple Sclerosis Journal - Experimental, Translational and Clinical	2022
36371974	The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions.	Comput Methods Programs Biomed	2022
35971322	Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.	Multiple Sclerosis Journal	2022
35963325	Transcranial direct current stimulation as a preventive treatment in multiple sclerosis? Preclinical evidence.	Exp Neurol	2022
35765217	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â¿¿years of follow-up in the DAYBREAK open-label extension trial.	Multiple Sclerosis Journal	2022
35759013	Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.	Journal of Neurology	2022
36017780	Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.	Neurodegenerative Disease Management	2022
36086905	Signs and symptoms of COVID-19 in patients with multiple sclerosis.	European Journal of Neurology	2022
35437271	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.	Neurology	2022
35877104	Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.	JAMA Neurology	2022
35495042	Visual Evoked Potentials to Monitor Myelin Cuprizone-Induced Functional Changes.	Front Neurosci	2022
36274376	The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis.	NeuroImage: Clinical	2022
35367873	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.	Mult Scler Relat Disord	2022
36201476	Connecting real-world digital mobility assessment to clinical outcomes for regulatory and clinical endorsement-the Mobilise-D study protocol.	PLoS One	2022
35675744	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.	Multiple Sclerosis and Related Disorders	2022
36063731	Emerging trends in multiple sclerosis research.	Multiple Sclerosis and Related Disorders	2022
35672479	Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.	Neurol Sci	2022
35480225	Tissue donations for multiple sclerosis research: current state and suggestions for improvement.	Brain Communications	2022
35917745	Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-Î².	Mult Scler Relat Disord	2022
36116382	EBV and multiple sclerosis: Setting the research agenda.	Multiple Sclerosis and Related Disorders	2022
36498739	Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis.	J Clin Med	2022
36553660	A Whole-Genome Sequencing Study Implicates GRAMD1B in Multiple Sclerosis Susceptibility.	Genes (Basel)	2022
34328824	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.	Multiple Sclerosis Journal	2022
34132146	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.	Multiple Sclerosis Journal	2022
35046084	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.	Neurology: Neuroimmunology and NeuroInflammation	2022
34921842	Improving reproducibility of motor evoked potentials in mice.	J Neurosci Methods	2022
35296189	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â¿¿years.	Multiple Sclerosis Journal	2022
35043454	Dose-dependent effect of myelin oligodendrocyte glycoprotein on visual function and optic nerve damage in experimental autoimmune encephalomyelitis.	J Neurosci Res	2022